Title:
キメラ抗原受容体（ＣＡＲ）並びにその製造及び使用方法
Document Type and Number:
Japanese Patent JP2017514471
Kind Code:
A
Abstract:
標的抗原を高レベルで発現する細胞を特異的に標的にすることができるキメラ抗原受容体（ＣＡＲ）及びＣＡＲ発現Ｔ細胞を提供する。同様に、ＣＡＲ Ｔ細胞療法で、抗原（例えば、癌細胞）を高レベルで発現する細胞を特異的に標的にする方法を提供する。本発明は、例えば、ある抗原を標的とする発現キメラＴ細胞受容体（ＣＡＲ）を含む単離されたトランスジェニック細胞であって、前記ＣＡＲは、前記抗原に対するＫｄが約５ｎＭ〜約５００ｎＭである、前記単離されたトランスジェニック細胞を提供する。
Inventors:
Cooper, Lawrence Jay N.
Hully Gibbons, Calsoe
Oliverless, Simon
Anne, Sony
Hully Gibbons, Calsoe
Oliverless, Simon
Anne, Sony
Application Number:
JP2016563936A
Publication Date:
June 08, 2017
Filing Date:
April 23, 2015
Export Citation:
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
International Classes:
C12N5/10; A61K35/17; A61P35/00; A61P37/06; C07K16/30; C07K16/32; C12N5/0783; C12N9/14
Foreign References:
| WO2012099973A2 | 2012-07-26 |
Other References:
CHMIELEWSKI M ET AL.: "T cell Activation by Antibody-like Immunoreceptors: Increase in Affinity of the Single-Chain Fragmen", JOURNAL OF IMMUNOLOGY, vol. 173, JPN6019006867, 2004, pages 7647 - 7653, XP055202108, ISSN: 0003986621, DOI: 10.4049/jimmunol.173.12.7647
GARRAIDO G. ET AL.: "Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinica", CANCER BIOLOGY & THERAPY, vol. 11, JPN6019006868, 2011, pages 373 - 382, XP055197571, ISSN: 0003986622, DOI: 10.4161/cbt.11.4.14097
SHEN C.J. ET AL.: "Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 6, JPN6019006869, 2013, pages 33-, ISSN: 0003986623
GUPTA P. ET AL.: "Development of an EGFRｖIII specific recombinant antibody", BMC BIOTECHNOLOGY, vol. 10, JPN6019006871, 2010, pages 72-, ISSN: 0003986624
ＢＵＬＬＡＩＮ S.S. ET AL.: "Genetically engineered T cells to target EGFRvIII expressing glioblastoma", JOURNAL OF NEUROONCOLOGY, vol. 94, JPN6019006872, 2009, pages 373 - 382, XP019732597, ISSN: 0003986625, DOI: 10.1007/s11060-009-9889-1
LORIMER I. A. J. ET AL.: "Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a si", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATS OF AMERICA, vol. 93, JPN6019006874, 1996, pages 14815 - 14820, XP002912821, ISSN: 0003986626, DOI: 10.1073/pnas.93.25.14815
GARRAIDO G. ET AL.: "Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinica", CANCER BIOLOGY & THERAPY, vol. 11, JPN6019006868, 2011, pages 373 - 382, XP055197571, ISSN: 0003986622, DOI: 10.4161/cbt.11.4.14097
SHEN C.J. ET AL.: "Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 6, JPN6019006869, 2013, pages 33-, ISSN: 0003986623
GUPTA P. ET AL.: "Development of an EGFRｖIII specific recombinant antibody", BMC BIOTECHNOLOGY, vol. 10, JPN6019006871, 2010, pages 72-, ISSN: 0003986624
ＢＵＬＬＡＩＮ S.S. ET AL.: "Genetically engineered T cells to target EGFRvIII expressing glioblastoma", JOURNAL OF NEUROONCOLOGY, vol. 94, JPN6019006872, 2009, pages 373 - 382, XP019732597, ISSN: 0003986625, DOI: 10.1007/s11060-009-9889-1
LORIMER I. A. J. ET AL.: "Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a si", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATS OF AMERICA, vol. 93, JPN6019006874, 1996, pages 14815 - 14820, XP002912821, ISSN: 0003986626, DOI: 10.1073/pnas.93.25.14815
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita